Company Pathfinder Cell Therapy, Inc. Other OTC
Equities
PFND
US70319A1060
Biotechnology & Medical Research
Business Summary
Sales per region
USD in Million | 2012 | Weight | 2013 | Weight | Delta |
---|---|---|---|---|---|
Russia
50.0
%
| 0 | 13.2 % | 0 | 50.0 % | +80.00% |
Czech Republic
18.5
%
| 0 | 13.2 % | 0 | 18.5 % | -33.33% |
Brazil
14.8
%
| 0 | 14.9 % | 0 | 14.8 % | -52.94% |
Hong Kong
11.1
%
| 0 | 32.5 % | 0 | 11.1 % | -83.78% |
Other Countries
5.6
%
| - | - | 0 | 5.6 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Rick Franklin
CEO | Chief Executive Officer | 78 | 11-09-01 |
John Benson
DFI | Director of Finance/CFO | 62 | 11-09-01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Rick Franklin
CEO | Chief Executive Officer | 78 | 11-09-01 |
John Benson
DFI | Director of Finance/CFO | 62 | 11-09-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 667,160,870 | 667,160,870 ( 100.00 %) | 0 | 100.00 % |
Company contact information
Pathfinder Cell Therapy, Inc.
12 Bow Street
02138-5104, Cambridge
+
http://www.pathfindercelltherapy.comSector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |